GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. - Test2 - elhamkhani - TriplyDB

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

http://www.wikidata.org/entity/Q34494154

about

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters Early implementation of QbD in biopharmaceutical development: a practical example XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic Evaluation of the use of therapeutic peptides for cancer treatment Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Protein-polymer conjugation-moving beyond PEGylation.Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male rats Teduglutide in Crohn's disease.Early engineering approaches to improve peptide developability and manufacturability.COMPARATIVE GUT PHYSIOLOGY SYMPOSIUM: Comparative physiology of glucagon-like peptide-2: Implications and applications for production and health of ruminants.Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.Porcine glucagon-like peptide-2 microspheres ameliorate inflammation in lipopolysaccharide-challenged weaning piglets.Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model.Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration.GLP2 Promotes Directed Differentiation from Osteosarcoma Cells to Osteoblasts and Inhibits Growth of Osteosarcoma Cells.

P2860

Q26801319-75B634C9-8BEF-4C09-8CF9-AD27E507D029 Q26830466-8C55D560-B458-485C-86F3-89CD0AA9D024 Q28550226-D4DB4EE3-3B7A-4BB7-8C67-BFAE206A30D7 Q29048586-BD8E5086-971B-4515-8885-32DB04CC7832 Q34149681-44A59C13-07FA-498D-9EA0-5ED75876BA92 Q35087618-2E994544-CB1E-470F-8D16-B0EE38322528 Q36171894-8F49FA78-941C-448D-80A9-50F9501756BB Q36220152-F0846D0C-D867-48FA-8129-01BDA5483FE2 Q36297218-4E77F4E5-5372-49F9-A780-6DFAB1FC12C2 Q38120028-9EC31C2E-D591-47DB-90AF-BA896BF72D06 Q38262021-BB351E62-6726-4221-AA0F-4C372058B01F Q42477615-2C5CF2CE-468F-4DA9-86A8-DB5BC76805E1 Q45216920-29408391-DBBD-4A69-96FE-44E730A723C0 Q47102857-0E8F69A6-1DD4-4BD0-9F64-2FA9B9BB430D Q47901428-5E640F95-66E6-4520-920E-25F9B71FCF71 Q51830867-13EABFB2-5587-4E82-8E8C-5A7075B2FC13 Q54233528-ABEA45DF-11F9-4990-A6D6-205F1B355F86 Q55363534-6D373922-C931-481A-91B4-7F84206F1059

P2860

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

http://www.wikidata.org/entity/Q34494154

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@ast

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@en

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@nl

type

label

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@ast

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@en

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@nl

prefLabel

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@ast

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@en

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@nl

P1433

Q34494154-0583048F-C782-4B10-90AE-B571C05476C8

P1476

Q34494154-EA0E246C-28E6-4FF1-9886-8641C7432C54

P2093

Q34494154-03034030-CD8F-42A7-825D-BDD38E63A27D

Q34494154-15488AAA-B086-49C4-BBD3-2B2D37438E5A

Q34494154-3022F5A2-EB69-45B5-81CF-AEBBF22D82FB

Q34494154-567A253B-F5D1-4932-911A-26280391DCA7

Q34494154-BC15A39A-420C-44D7-9C33-694323769A9E

Q34494154-E1F64FC9-0099-4700-A19C-96B85506BD43

Q34494154-E79F336B-58E0-4867-9411-38C9577F850A

Q34494154-F3BFC224-2457-4563-A5EC-8A6BC3E7B1BB

P2860

Q34494154-0A91367A-5CEA-486E-8CD9-4F10CE936A67

Q34494154-0F145A1E-F283-417E-8BB5-D7D492668CE4

Q34494154-1AE60B8D-88A3-4BED-97EA-53BE1CC8A00B

Q34494154-1FA5ADD3-DC1C-41AB-A0EF-04A17AEFE9B5

Q34494154-2D5475C2-E0A8-4409-BDF0-B1E9B2185FCB

Q34494154-31BCCB31-B96A-4913-84CE-CFB3E0C73ADF

Q34494154-37810280-F964-4A4F-B64F-0CE470A71F4C

Q34494154-4068EEFB-2E48-463E-AA07-5C391A1689B1

Q34494154-40A5B288-B85C-42AD-B453-B464C3C79F0E

Q34494154-441607CD-6124-43F3-808C-5A90C6F3F65B

P304

Q34494154-606B121E-D0B7-421D-A523-42940B240EAB

P31

Q34494154-0909B1E9-6850-45AC-991F-92CBEC4E42D5

P356

Q34494154-705D240C-0D1C-4E2A-A300-A222BE87F687

P407

Q34494154-F5D49682-1A9E-4058-9090-D1498537D1BF

P433

Q34494154-E2890582-40B0-460F-B1C9-FE1ECE4124D0

P478

Q34494154-1F82BDA5-A484-4203-A7B8-31BD8736D9AE

P577

Q34494154-292D218F-A248-4639-88E5-37690D8C9FC0

P5875

Q34494154-76166BE9-C625-4B75-9F84-3D8B69F1D864

P698

Q34494154-2C3C4DF7-21A0-4870-B9AA-7F61CEE408B4

P921

Q34494154-6EB66F79-4BF4-4222-A440-C0203580B38D

Q34494154-D82C8749-4308-4ACE-ABF2-6544F7228C0D

P932

Q34494154-B87C7BE4-B38A-4319-B75F-97B95ADF5F1F

P356

JOURNAL.PONE.0050630

P1433

P1476

GLP2-2G-XTEN: a pharmaceutical ...... n a rat Crohn's disease model.

@en

P2093

Benjamin Spink

http://www.w3.org/2001/XMLSchema#string

Bryant McLaughlin

http://www.w3.org/2001/XMLSchema#string

Chia-wei Wang

http://www.w3.org/2001/XMLSchema#string

Susan E Alters

http://www.w3.org/2001/XMLSchema#string

Tigran Lachinyan

http://www.w3.org/2001/XMLSchema#string

Vladimir Podust

http://www.w3.org/2001/XMLSchema#string

Volker Schellenberger

http://www.w3.org/2001/XMLSchema#string

Willem P C Stemmer

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Certolizumab pegol for the treatment of Crohn's disease

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis

Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

Enteroendocrine localization of GLP-2 receptor expression in humans and rodents.

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.

P304

e50630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0050630

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233789905

http://www.w3.org/2001/XMLSchema#string

P698

23189208

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

3506575

http://www.w3.org/2001/XMLSchema#string